- What it does: Retrace is a dental AI company focused on treatment planning and case presentation rather than radiograph analysis. We have not been able to confirm FDA 510(k) clearance for Retrace as of February 2026, and practices should verify its regulatory status directly with the company before clinical use.
- Regulatory: No clearance confirmed
- Pricing: Not published (Contact sales)
Retrace targets the treatment planning and case presentation side of dental AI, which is a different niche from the diagnostic imaging tools (Overjet, Pearl, VideaHealth) that dominate the dental AI conversation. However, we were unable to confirm FDA 510(k) clearance for Retrace as of February 2026. The product appears in dental AI market listings and directories, but practices should independently verify its regulatory status and clinical validation before incorporating it into clinical workflows. If you are evaluating dental AI tools, start with the FDA-cleared diagnostic platforms and assess Retrace as a potential complement for the treatment planning workflow, after confirming its current regulatory standing.
Retrace vs alternatives
Other practice management tools we track: CareStack (From $829), Open Dental (From $199), Oryx (From $650), tab32 (From $125).
What Retrace does
- AI-assisted treatment planning
- Case presentation to patients
How much does Retrace cost?
Retrace does not publish pricing; it is quoted by sales (Contact sales). Pricing is not published; contact the vendor.
- Addresses the treatment planning and case presentation workflow rather than diagnostic imaging
- May complement diagnostic AI tools like Overjet, Pearl, or VideaHealth
- No confirmed FDA 510(k) clearance. Practices should verify regulatory status before clinical use
- Less publicly documented than established dental AI competitors
Where it fits
- Generating treatment plans with AI assistance
- Presenting treatment options visually to patients
What we have not verified
We have not been able to confirm FDA 510(k) clearance for Retrace as of February 2026. The product appears in various dental AI market listings and directories, but a search of public FDA databases did not return a confirmed clearance. This does not necessarily mean the product lacks clearance; it may operate under a classification that does not require 510(k) review, or clearance information may not yet be reflected in public records. Practices considering Retrace should verify its current regulatory status directly with the company before any clinical use.
Common questions
Is Retrace FDA cleared?
We could not confirm an FDA 510(k) clearance for Retrace as of Oct 21, 2026.
Corrections and updates
- 2026-10-21: Retrace's website (retrace.ai) failed to load with an SSL error on Oct 21, 2026; product availability could not be confirmed.